Body Composition Changes in Gastric Cancer Patients during Preoperative FLOT Therapy: Preliminary Results of an Italian Cohort Study.
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Body Composition
/ drug effects
Body Mass Index
Combined Modality Therapy
Docetaxel
/ administration & dosage
Female
Fluorouracil
/ administration & dosage
Humans
Italy
Leucovorin
/ administration & dosage
Male
Middle Aged
Neoadjuvant Therapy
/ adverse effects
Oxaliplatin
/ administration & dosage
Retrospective Studies
Sarcopenia
/ chemically induced
Stomach Neoplasms
/ diagnostic imaging
Tomography, X-Ray Computed
FLOT
SMI
adipose tissue
body composition
gastric cancer
muscle mass
neoadjuvant chemotherapy
personalized medicine
sarcopenia
toxicity
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
16 Mar 2021
16 Mar 2021
Historique:
received:
05
02
2021
revised:
10
03
2021
accepted:
12
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
21
5
2021
Statut:
epublish
Résumé
The impact of the new chemotherapy, fluorouracil plus leucovorin, oxaliplatin, and docetaxel (FLOT) on body composition in gastric cancer (GC) patients remains unknown. We assessed body composition changes of GC patients receiving the FLOT regimen and their impact on treatment outcomes. Preoperative pre- and post-FLOT computed tomography (CT) scans of advanced GC patients were studied. Lumbar skeletal muscle index (SMI) and adipose indices were calculated before and after FLOT. A total of 26 patients were identified between April 2019 and January 2020. Nineteen patients were sarcopenic at diagnosis. The mean BMI decreased (from 24.4 ± 3.7 to 22.6 ± 3.1; Almost three-quarters (73.1%) of GC patients were sarcopenic at diagnosis. Preoperative FLOT was associated with a further reduction in SMI, BMI, and VAI. These changes were not associated with short-term outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
The impact of the new chemotherapy, fluorouracil plus leucovorin, oxaliplatin, and docetaxel (FLOT) on body composition in gastric cancer (GC) patients remains unknown. We assessed body composition changes of GC patients receiving the FLOT regimen and their impact on treatment outcomes.
METHODS
METHODS
Preoperative pre- and post-FLOT computed tomography (CT) scans of advanced GC patients were studied. Lumbar skeletal muscle index (SMI) and adipose indices were calculated before and after FLOT.
RESULTS
RESULTS
A total of 26 patients were identified between April 2019 and January 2020. Nineteen patients were sarcopenic at diagnosis. The mean BMI decreased (from 24.4 ± 3.7 to 22.6 ± 3.1;
CONCLUSIONS
CONCLUSIONS
Almost three-quarters (73.1%) of GC patients were sarcopenic at diagnosis. Preoperative FLOT was associated with a further reduction in SMI, BMI, and VAI. These changes were not associated with short-term outcomes.
Identifiants
pubmed: 33809587
pii: nu13030960
doi: 10.3390/nu13030960
pmc: PMC7999770
pii:
doi:
Substances chimiques
Oxaliplatin
04ZR38536J
Docetaxel
15H5577CQD
Leucovorin
Q573I9DVLP
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Oncology. 2020;98(1):29-34
pubmed: 31509833
Ann Surg Oncol. 2018 Nov;25(12):3596-3603
pubmed: 30167910
Cancers (Basel). 2020 Oct 31;12(11):
pubmed: 33142864
Anticancer Res. 2018 Oct;38(10):5859-5866
pubmed: 30275211
Int J Surg. 2018 Mar;51:120-127
pubmed: 29413875
Clin Nutr. 2007 Dec;26(6):698-709
pubmed: 17683831
Lancet Oncol. 2016 Dec;17(12):1697-1708
pubmed: 27776843
Nutrition. 2018 Jun;50:74-81
pubmed: 29547797
JPEN J Parenter Enteral Nutr. 2019 Jan;43(1):32-40
pubmed: 30175461
J Surg Oncol. 2015 Sep;112(4):403-7
pubmed: 26331988
BJS Open. 2020 Oct;4(5):847-854
pubmed: 32841538
Eur J Surg Oncol. 2020 Apr;46(4 Pt A):620-625
pubmed: 31668977
Clin Nutr. 2020 Jul;39(7):2045-2054
pubmed: 31718876
J Cachexia Sarcopenia Muscle. 2016 Sep;7(4):458-66
pubmed: 27030813
J Clin Oncol. 2016 Apr 20;34(12):1339-44
pubmed: 26903572
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Medicine (Baltimore). 2020 Nov 20;99(47):e23363
pubmed: 33217879
Surg Obes Relat Dis. 2021 Mar;17(3):575-584
pubmed: 33262031
Eur J Transl Myol. 2018 Jun 06;28(2):7590
pubmed: 29991992
Ann Oncol. 2016 Sep;27(suppl 5):v38-v49
pubmed: 27664260
Front Physiol. 2016 Oct 19;7:472
pubmed: 27807421
Lancet Oncol. 2011 May;12(5):489-95
pubmed: 21296615
World J Surg Oncol. 2020 Apr 7;18(1):68
pubmed: 32264904
Front Oncol. 2013 Oct 07;3:262
pubmed: 24109590
Clin Nutr. 2012 Feb;31(1):74-7
pubmed: 21875767
Ann Oncol. 2019 Aug 1;30(8):1395-1397
pubmed: 31168599
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
Support Care Cancer. 2020 Aug;28(8):3965-3977
pubmed: 32335732
World J Surg. 2021 Mar;45(3):815-821
pubmed: 33179125
World J Surg Oncol. 2016 Oct 19;14(1):268
pubmed: 27756322
Clin Nutr ESPEN. 2020 Aug;38:28-42
pubmed: 32690170
Int J Gynecol Cancer. 2020 May;30(5):654-663
pubmed: 32241875
Cancers (Basel). 2020 Jul 04;12(7):
pubmed: 32635536
PLoS One. 2014 Jan 30;9(1):e86941
pubmed: 24497999
J Gastric Cancer. 2018 Sep;18(3):242-252
pubmed: 30276001
J Hum Nutr Diet. 2021 Jan 25;:
pubmed: 33491826
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
PLoS One. 2015 Oct 05;10(10):e0139749
pubmed: 26437072
Lancet. 2019 May 11;393(10184):1948-1957
pubmed: 30982686